FR20C1045I2 - Antidotes pour inhibiteurs du facteur xa et procedes d'utilisation associes - Google Patents

Antidotes pour inhibiteurs du facteur xa et procedes d'utilisation associes

Info

Publication number
FR20C1045I2
FR20C1045I2 FR20C1045C FR20C1045C FR20C1045I2 FR 20C1045 I2 FR20C1045 I2 FR 20C1045I2 FR 20C1045 C FR20C1045 C FR 20C1045C FR 20C1045 C FR20C1045 C FR 20C1045C FR 20C1045 I2 FR20C1045 I2 FR 20C1045I2
Authority
FR
France
Prior art keywords
antidotes
inhibitors
factor
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR20C1045C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Portola Pharmaceuticals LLC
Original Assignee
Portola Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharmaceuticals LLC filed Critical Portola Pharmaceuticals LLC
Publication of FR20C1045I1 publication Critical patent/FR20C1045I1/fr
Application granted granted Critical
Publication of FR20C1045I2 publication Critical patent/FR20C1045I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
FR20C1045C 2007-09-28 2020-09-23 Antidotes pour inhibiteurs du facteur xa et procedes d'utilisation associes Active FR20C1045I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97634307P 2007-09-28 2007-09-28
US9057408P 2008-08-20 2008-08-20
PCT/US2008/078014 WO2009042962A2 (en) 2007-09-28 2008-09-26 Antidotes for factor xa inhibitors and methods of using the same
EP08834136.7A EP2193196B1 (en) 2007-09-28 2008-09-26 Antidotes for factor xa inhibitors and methods of using the same

Publications (2)

Publication Number Publication Date
FR20C1045I1 FR20C1045I1 (pt) 2020-10-30
FR20C1045I2 true FR20C1045I2 (fr) 2021-08-27

Family

ID=40481812

Family Applications (1)

Application Number Title Priority Date Filing Date
FR20C1045C Active FR20C1045I2 (fr) 2007-09-28 2020-09-23 Antidotes pour inhibiteurs du facteur xa et procedes d'utilisation associes

Country Status (27)

Country Link
US (8) US8153590B2 (pt)
EP (4) EP2915564B1 (pt)
JP (6) JP5637561B2 (pt)
KR (4) KR101698214B1 (pt)
CN (4) CN101802188B (pt)
AU (6) AU2008304192B9 (pt)
BR (2) BR122022001846B1 (pt)
CA (1) CA2697583C (pt)
CY (2) CY1118482T1 (pt)
DK (3) DK3078743T3 (pt)
ES (3) ES2597436T3 (pt)
FR (1) FR20C1045I2 (pt)
HK (1) HK1210443A1 (pt)
HR (2) HRP20161255T1 (pt)
HU (4) HUE050063T2 (pt)
IL (4) IL203993A (pt)
LT (3) LT2193196T (pt)
MX (1) MX2010003095A (pt)
NL (1) NL301063I2 (pt)
NO (2) NO2019040I1 (pt)
NZ (1) NZ583944A (pt)
PL (3) PL2915564T3 (pt)
PT (3) PT2193196T (pt)
SG (1) SG185263A1 (pt)
SI (3) SI2193196T1 (pt)
WO (1) WO2009042962A2 (pt)
ZA (2) ZA201002039B (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
CA2651303A1 (en) 2006-05-05 2007-11-15 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
DK3078743T3 (da) * 2007-09-28 2020-08-10 Portola Pharm Inc Antidoter til faktor xa-inhibitorer og fremgangsmåder til anvendelse af disse
WO2010056765A2 (en) 2008-11-14 2010-05-20 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
ES2773766T3 (es) 2008-12-19 2020-07-14 Baxalta GmbH Inhibidores de TFPI y métodos de uso
PT2414517T (pt) 2009-03-30 2016-12-27 Portola Pharm Inc Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
CN102625712B (zh) 2009-07-15 2017-07-25 博尔托拉制药公司 用于因子xa抑制剂的解毒剂的单位剂量制剂及其使用方法
GB0916576D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
EP2316931B1 (de) 2009-10-30 2016-12-28 Senova Gesellschaft für Biowissenschaft und Technik mbH Polymergekoppelte Peptidasen
WO2011075602A1 (en) * 2009-12-17 2011-06-23 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
CA2784921A1 (en) 2009-12-17 2011-07-14 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor xa inhibitor
TWI513466B (zh) 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
AU2011227714B2 (en) 2010-03-19 2014-09-04 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
AR082804A1 (es) 2010-09-01 2013-01-09 Portola Pharm Inc Formas cristalinas de un inhibidor del factor xa
TW201240664A (en) * 2010-09-01 2012-10-16 Portola Pharm Inc Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor
CA2824885A1 (en) * 2011-01-19 2012-07-26 Bayer Intellectual Property Gmbh Binding proteins to inhibitors of coagulation factors
FR2972114B1 (fr) * 2011-03-01 2013-03-15 Univ Grenoble 1 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
CA2827787A1 (en) 2011-03-30 2012-10-04 Boehringer Ingelheim International Gmbh Anticoagulant antidotes
US9371522B2 (en) 2011-09-30 2016-06-21 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
EA027603B1 (ru) * 2011-11-29 2017-08-31 Перосфере Инк. Производные пиперазина, реверсирующие действие антикоагулянтов
US20130230901A1 (en) 2012-02-14 2013-09-05 Portola Pharmaceuticals, Inc. Process for making recombinant antidote to factor xa inhibitor
WO2013123248A1 (en) * 2012-02-16 2013-08-22 Portola Pharmaceuticals, Inc. MODULATION OF FACTOR Xa INHIBITOR MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE
CA2867363C (en) 2012-03-21 2023-02-28 Baxter International Inc. Tfpi inhibitors and methods of use
KR102210574B1 (ko) * 2012-06-14 2021-02-01 포톨라 파마슈티컬스, 인코포레이티드 재조합 인자 Xa 유도체의 정제방법
ES2704083T3 (es) * 2012-07-25 2019-03-14 Catalyst Biosciences Inc Polipéptidos de factor x modificados y usos de los mismos
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
FR3000895B1 (fr) * 2013-01-11 2017-02-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Sa Utilisation d'antidotes d'inhibiteurs de la coagulation indiques dans la prevention ou le traitement de pathologies thromboemboliques
CN105025920A (zh) * 2013-01-24 2015-11-04 博尔托拉制药公司 具有因子Xa衍生物的组织因子途径抑制剂的抑制
US20150343034A1 (en) 2013-01-31 2015-12-03 Pfizer Inc. Compositions and methods for counteracting factor xa inhibition
FR3007410B1 (fr) * 2013-06-21 2016-05-27 Lab Francais Du Fractionnement Facteur x depourvu de domaine gla
MX2016003871A (es) * 2013-09-24 2016-08-04 Pfizer Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion.
EP3063170A4 (en) * 2013-11-01 2017-06-28 The Children's Hospital of Philadelphia Compositions and methods for increasing the half-life of factor xa
CN106536566A (zh) * 2014-05-26 2017-03-22 莱顿教学医院 用于出血治疗的促止血蛋白
WO2016019145A1 (en) * 2014-07-31 2016-02-04 Haemonetics Corporation Detection and classification of an anticoagulant using a clotting assay
US10676731B2 (en) 2014-08-19 2020-06-09 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor IX function
JP6742986B2 (ja) * 2014-08-20 2020-08-19 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子解毒剤の凍結乾燥製剤
CN105030703B (zh) * 2015-06-23 2018-03-23 上海旭东海普药业有限公司 一种防治疗栓塞性疾病的利伐沙班片及其制备方法
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
CN108883160B (zh) * 2016-02-24 2022-06-28 博尔托拉制药公司 因子xa解毒剂的冻干制剂
US10640822B2 (en) 2016-02-29 2020-05-05 Iridia, Inc. Systems and methods for writing, reading, and controlling data stored in a polymer
US10438662B2 (en) 2016-02-29 2019-10-08 Iridia, Inc. Methods, compositions, and devices for information storage
US10859562B2 (en) 2016-02-29 2020-12-08 Iridia, Inc. Methods, compositions, and devices for information storage
KR20180123062A (ko) * 2016-02-29 2018-11-14 이리디아, 인크. 정보 저장을 위한 방법, 조성물, 및 장치
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
CA3027457A1 (en) 2016-06-17 2017-12-21 Portola Pharmaceuticals, Inc. Preparation of factor xa derivatives
WO2018115235A1 (en) 2016-12-22 2018-06-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Antidotes to anti-coagulant drugs allowing diagnosis and treatment
US11168147B2 (en) 2016-12-23 2021-11-09 Novartis Ag Factor XI antibodies and methods of use
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
EP3672520A4 (en) * 2017-08-21 2021-06-30 Allele Biotechnology And Pharmaceuticals, Inc. LIGHT ABSORBING COMPOSITIONS AND METHODS OF USE
WO2019096874A1 (en) 2017-11-15 2019-05-23 Novo Nordisk A/S Factor x binders enhancing fx activation
JP2021527435A (ja) * 2018-06-19 2021-10-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子阻害剤に対する解毒剤
AU2019322287A1 (en) * 2018-08-14 2021-03-11 Jiangsu Hengrui Medicine Co., Ltd. Injectable pharmaceutical composition and preparation method therefor
US11655465B1 (en) 2019-05-02 2023-05-23 Iridia, Inc. Enzymes and systems for synthesizing DNA
WO2021026254A2 (en) * 2019-08-08 2021-02-11 Portola Pharmaceuticals, Inc. Compositions and methods for preparing factor xa and derivatives
US11837302B1 (en) 2020-08-07 2023-12-05 Iridia, Inc. Systems and methods for writing and reading data stored in a polymer using nano-channels
CN113484386B (zh) * 2021-05-21 2024-02-13 郑州轻工业大学 一种金属聚酞菁纳米材料的制备方法及其应用，适配体传感器及其制备方法
CN114681597A (zh) * 2022-03-11 2022-07-01 兆科药业（合肥）有限公司 蝰蛇蛇毒血凝酶在制备用于逆转凝血因子Xa抑制剂的抗凝作用的药物中的应用

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH596313A5 (pt) * 1975-05-30 1978-03-15 Battelle Memorial Institute
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3590766C2 (pt) 1985-03-30 1991-01-10 Marc Genf/Geneve Ch Ballivet
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
US4818700A (en) 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4812405A (en) 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US6270961B1 (en) 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5120537A (en) * 1989-06-14 1992-06-09 Oklahoma Medical Research Foundation Factor xa based anticoagulant compositions
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5686073A (en) 1990-05-23 1997-11-11 The University Of Iowa Research Foundation Polyclonal and monoclonal antibodies against a 43 KDA dystrophin associated protein
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
US5583107A (en) * 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5597799A (en) * 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
US5278144A (en) * 1990-09-04 1994-01-11 Cor Therapeutics, Inc. Antithrombosis agents
CA2103577A1 (en) 1991-02-07 1992-08-08 Michael Kahn Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
JPH06511149A (ja) 1991-09-13 1994-12-15 カイロン　コーポレイション 免疫反応性ｃ型肝炎ウイルスのポリペプチド組成物
WO1993009804A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
US5766886A (en) 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
WO1993018782A1 (en) 1992-03-20 1993-09-30 Cor Therapeutics, Inc. Glycosylation-mediated inhibition of factor x
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
CN1263864C (zh) 1993-10-25 2006-07-12 坎吉公司 重组腺病毒载体及其使用方法
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5952172A (en) 1993-12-10 1999-09-14 California Institute Of Technology Nucleic acid mediated electron transfer
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
DE4430205A1 (de) * 1994-08-26 1996-02-29 Behringwerke Ag Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung
US5589571A (en) 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US6709659B1 (en) 1996-08-02 2004-03-23 Zymogenetics, Inc. Antibodies that bind testis-specific insulin homolog polypeptides
SE9604744D0 (sv) 1996-12-20 1996-12-20 Pharmacia & Upjohn Ab A modified coagulation agent
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
WO1998039456A1 (en) * 1997-03-07 1998-09-11 Washington University Factor x variant
JPH1149800A (ja) 1997-06-05 1999-02-23 Fujimori Kogyo Kk アンヒドロトロンビンの合成方法
WO1999054342A1 (en) 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6322788B1 (en) 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
JP2002530081A (ja) 1998-11-18 2002-09-17 ジェネンテック・インコーポレーテッド 親抗体より高度な結合親和性を持つ抗体変異体
AU3629800A (en) 1999-03-16 2000-10-04 Children's Hospital Of Philadelphia, The Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US6258559B1 (en) 1999-03-22 2001-07-10 Zymogenetics, Inc. Method for producing proteins in transformed Pichia
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US6858599B2 (en) 1999-06-30 2005-02-22 Mochida Pharmaceutical Co., Ltd. Tricyclic compound having spiro union
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
EP1095933A1 (en) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
US6660885B2 (en) 2000-03-13 2003-12-09 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
ATE549347T1 (de) 2000-09-08 2012-03-15 Schering Corp Gene von säugetiere, und damit verbundene reagentien, methoden
US7070740B1 (en) 2000-09-28 2006-07-04 Beckman Coulter, Inc. Method and apparatus for processing biomolecule arrays
US20030064414A1 (en) 2001-03-30 2003-04-03 Benecky Michael J. Rapid assessment of coagulation activity in whole blood
WO2002090599A1 (en) 2001-05-09 2002-11-14 Genetic Id, Inc. Universal microarray system
US6989267B2 (en) 2001-07-02 2006-01-24 Agilent Technologies, Inc. Methods of making microarrays with substrate surfaces having covalently bound polyelectrolyte films
DE10155075A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Cyclische Sulfonamide
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
CN1480466A (zh) * 2002-09-03 2004-03-10 �й������ž�����ҽѧ��ѧԺ����ҽ 一类溶栓抗凝双功能融合蛋白及应用
US20040198660A1 (en) 2002-11-06 2004-10-07 Petersen Lars Christian Tissue factor antagonist and protein C polypeptide compositions
US7247654B2 (en) 2003-06-04 2007-07-24 Bristol-Myers Squibb Company 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors
JP2007527539A (ja) 2004-03-05 2007-09-27 ザ スクリプス リサーチ インスティテュート ハイスループットグリカンマイクロアレイ
JP4441336B2 (ja) 2004-06-11 2010-03-31 日本碍子株式会社 マイクロアレイの製造方法
US9223929B2 (en) 2005-03-14 2015-12-29 The California Institute Of Technology Method and apparatus for detection, identification and quantification of single-and multi-analytes in affinity-based sensor arrays
US7119179B1 (en) 2005-03-21 2006-10-10 Los Alamos National Security, Llc Preparation of high nitrogen compound and materials therefrom
US9164108B2 (en) 2005-03-22 2015-10-20 Sri International Liposome-based microarray and methods of use thereof
ATE549317T1 (de) 2005-11-08 2012-03-15 Millennium Pharm Inc Pharmazeutische salze und polymorphe aus n-(5- chloro-2-pyridinyl)-2-ää4- ä(dimethylamino)iminomethylübenzoylüaminoü-5- methoxy-benzamid, einem faktor-xa-hemmer
US20070111322A1 (en) 2005-11-15 2007-05-17 Lin-Cheng Yang Novel method of using inject printing for creating microarrays
MX336958B (es) * 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
DK3078743T3 (da) 2007-09-28 2020-08-10 Portola Pharm Inc Antidoter til faktor xa-inhibitorer og fremgangsmåder til anvendelse af disse
WO2010056765A2 (en) 2008-11-14 2010-05-20 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
EP2358874B1 (en) 2008-12-19 2017-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders
PT2414517T (pt) * 2009-03-30 2016-12-27 Portola Pharm Inc Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
CN102625712B (zh) 2009-07-15 2017-07-25 博尔托拉制药公司 用于因子xa抑制剂的解毒剂的单位剂量制剂及其使用方法

Also Published As

Publication number Publication date
NO2019040I1 (no) 2019-11-08
KR102069498B1 (ko) 2020-01-23
SI3078743T1 (sl) 2020-08-31
JP2022153574A (ja) 2022-10-12
CN103446579B (zh) 2015-04-22
PL2193196T3 (pl) 2017-07-31
IL255397B (en) 2019-03-31
HRP20161255T1 (hr) 2016-12-02
ZA201406514B (en) 2016-10-26
CA2697583A1 (en) 2009-04-02
LTPA2020540I1 (lt) 2021-01-11
EP3824902A1 (en) 2021-05-26
HUE031647T2 (en) 2017-07-28
KR102271404B1 (ko) 2021-07-02
EP3078743B1 (en) 2020-06-24
US8889129B2 (en) 2014-11-18
CN102559644B (zh) 2015-03-25
NZ583944A (en) 2012-06-29
WO2009042962A2 (en) 2009-04-02
ES2849426T3 (es) 2021-08-18
ZA201002039B (en) 2015-11-25
JP6300885B2 (ja) 2018-03-28
US10675335B2 (en) 2020-06-09
EP2915564A1 (en) 2015-09-09
AU2013205326A8 (en) 2013-06-06
IL203993A (en) 2017-11-30
IL264886B (en) 2020-03-31
FR20C1045I1 (pt) 2020-10-30
IL203993A0 (en) 2011-07-31
BR122022001846B1 (pt) 2022-12-27
DK2193196T3 (en) 2016-11-07
IL255397A0 (en) 2017-12-31
EP3078743A1 (en) 2016-10-12
HK1210443A1 (en) 2016-04-22
AU2008304192B9 (en) 2024-02-01
JP2014218521A (ja) 2014-11-20
US9388401B2 (en) 2016-07-12
AU2008304192A1 (en) 2009-04-02
AU2013205326A1 (en) 2013-05-09
EP2193196B1 (en) 2016-07-13
US20120269788A1 (en) 2012-10-25
ES2597436T3 (es) 2017-01-18
US8455441B2 (en) 2013-06-04
JP2020109113A (ja) 2020-07-16
EP2193196A2 (en) 2010-06-09
JP2017043632A (ja) 2017-03-02
CY1118482T1 (el) 2017-07-12
CN101802188B (zh) 2013-08-21
LT2193196T (lt) 2016-12-12
KR20100077172A (ko) 2010-07-07
NO2020033I1 (no) 2020-09-23
SI2915564T1 (sl) 2021-03-31
PT2193196T (pt) 2016-10-24
KR101698214B1 (ko) 2017-01-20
US20140079684A1 (en) 2014-03-20
AU2019204123A1 (en) 2019-07-04
WO2009042962A3 (en) 2009-06-04
AU2008304192A2 (en) 2010-04-08
CN102533702A (zh) 2012-07-04
US20160354449A1 (en) 2016-12-08
AU2014210620A1 (en) 2014-08-28
DK2915564T3 (da) 2021-02-08
HUS2000057I1 (hu) 2021-01-28
LTC3078743I2 (lt) 2022-06-10
PT2915564T (pt) 2021-02-09
KR20160025038A (ko) 2016-03-07
HUE050063T2 (hu) 2020-11-30
PL3078743T3 (pl) 2020-11-02
AU2008304192B2 (en) 2014-05-15
CN101802188A (zh) 2010-08-11
US20240082367A1 (en) 2024-03-14
EP2915564B1 (en) 2020-11-04
US8153590B2 (en) 2012-04-10
HUE052423T2 (hu) 2021-04-28
AU2014210620B2 (en) 2016-05-12
KR20200009131A (ko) 2020-01-29
BRPI0816837B1 (pt) 2022-10-18
US20200276280A1 (en) 2020-09-03
NL301063I1 (pt) 2020-09-16
HRP20201071T1 (hr) 2020-10-30
JP2018100290A (ja) 2018-06-28
BRPI0816837A2 (pt) 2020-08-18
US20090098119A1 (en) 2009-04-16
ES2796623T3 (es) 2020-11-27
JP2010539945A (ja) 2010-12-24
DK3078743T3 (da) 2020-08-10
IL272926A (en) 2020-04-30
PT3078743T (pt) 2020-07-15
SG185263A1 (en) 2012-11-29
US11839646B2 (en) 2023-12-12
JP6047127B2 (ja) 2016-12-21
AU2017200212A1 (en) 2017-02-02
LT3078743T (lt) 2020-09-25
SI2193196T1 (sl) 2017-01-31
US9062298B2 (en) 2015-06-23
AU2021218033A1 (en) 2021-09-09
CA2697583C (en) 2016-04-12
MX2010003095A (es) 2010-04-09
CN103446579A (zh) 2013-12-18
US20150057228A1 (en) 2015-02-26
PL2915564T3 (pl) 2021-07-19
JP5637561B2 (ja) 2014-12-10
KR20170100071A (ko) 2017-09-01
US20140044773A1 (en) 2014-02-13
CY1123504T1 (el) 2021-06-25
NL301063I2 (nl) 2021-06-23
WO2009042962A9 (en) 2009-09-11
CN102559644A (zh) 2012-07-11

Similar Documents

Publication Publication Date Title
FR20C1045I2 (fr) Antidotes pour inhibiteurs du facteur xa et procedes d'utilisation associes
FR20C1033I1 (fr) Anticorps anti-cd79b, immuno-conjugues et procedes d'utilisation
CY2019010I1 (el) Νεες ενωσεις και συνθεσεις και μεθοδοι χρησης
DK2015754T3 (da) Anvendelse af dpp-iv-inhibitorer
FR2905243B1 (fr) Applicateurs pour cosmetique et procedes de fabrication
ATE531720T1 (de) Aza-benzofuranylverbindungen und anwendungsverfahren dafür
DK2091945T3 (da) Nye inhibitorer af glutaminylcyclase
EP2224928A4 (en) NOVEL INHIBITORS OF SEH AND THEIR USE
DK2214487T3 (da) Nye sEH-inhibitorer og deres anvendelse
EP2217068A4 (en) NOVEL INHIBITORS OF SEH AND THEIR USE
EP2209376A4 (en) NEW SEH-HEMMER AND ITS USE
DK2254881T3 (da) Chlorothiophenamides som inhibitorer af koagulationsfaktorerne xa og thrombin
DK1976853T3 (da) Nye forbindelser og anvendelse heraf
FR2906734B1 (fr) Sonoreacteur et utilisation d'un sonoreacteur
FI20075320A0 (fi) Uusia käyttökelpoisia inhibiittoreita
FR2900539B1 (fr) Abreuvoir pour utilisation en aviculture
FI20070495A0 (fi) Aktivaattori ja niiden terapeuttiset sovellukset
FI20075803A0 (fi) Kalvonjakolaite ja kalvonjakolaitteen käyttö